Literature DB >> 28168312

Valproic acid-induced hyperammonemic encephalopathy in a full-term neonate: a brief review and case report.

Pavla Pokorná1,2,3, Karolina Hronová4, Martin Šíma4, Ondřej Slanař4, Petr Klement5, John N van den Anker6,7,8,9,10, Dick Tibboel5,11.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28168312     DOI： 10.1007/s00228-017-2208-4

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  15 in total

1.  Intravenous valproate in pediatric epilepsy patients with refractory status epilepticus.

Authors:  M A Uberall; R Trollmann; U Wunsiedler; D Wenzel
Journal:  Neurology       Date:  2000-06-13       Impact factor: 9.910

2.  Intravenous valproate dosing in neonates.

Authors:  I Alfonso; L A Alvarez; J Gilman; C Dunoyer; K Yelin; O Papazian
Journal:  J Child Neurol       Date:  2000-12       Impact factor: 1.987

3.  Summary proceedings from the neurology group on neonatal seizures.

Authors:  Robert R Clancy
Journal:  Pediatrics       Date:  2006-03       Impact factor: 7.124

4.  A theoretical method for normalizing total serum valproic acid concentration in hypoalbuminemic patients.

Authors:  Jesús Hermida; J Carlos Tutor
Journal:  J Pharmacol Sci       Date:  2005-04       Impact factor: 3.337

5.  Influence of glutamine synthetase gene polymorphisms on the development of hyperammonemia during valproic acid-based therapy.

Authors:  Kazuyuki Inoue; Toshiki Takahashi; Yoshiaki Yamamoto; Eri Suzuki; Yukitoshi Takahashi; Katsumi Imai; Yushi Inoue; Keita Hirai; Daiki Tsuji; Kunihiko Itoh
Journal:  Seizure       Date:  2015-11-06       Impact factor: 3.184

Review 6.  Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review.

Authors:  M F B Silva; C C P Aires; P B M Luis; J P N Ruiter; L IJlst; M Duran; R J A Wanders; I Tavares de Almeida
Journal:  J Inherit Metab Dis       Date:  2008-04-04       Impact factor: 4.982

Review 7.  Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence?

Authors:  Philippe E R Lheureux; Andrea Penaloza; Soheil Zahir; Mireille Gris
Journal:  Crit Care       Date:  2005-06-10       Impact factor: 9.097

8.  Effects of valproic acid on organic acid metabolism in children: a metabolic profiling study.

Authors:  K E Price; R E Pearce; U C Garg; B A Heese; L D Smith; J E Sullivan; M J Kennedy; J F Bale; R M Ward; T K H Chang; F S Abbott; J S Leeder
Journal:  Clin Pharmacol Ther       Date:  2011-05-04       Impact factor: 6.875

9.  Adverse events in a newborn on valproate therapy due to loss-of-function mutations in CYP2C9.

Authors:  Andrea Nagy; Tamás Bűdi; Manna Temesvári; Zsuzsa Szever; Pál Tamás Szabó; Katalin Monostory
Journal:  Epilepsy Behav Case Rep       Date:  2015-09-22

10.  Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy.

Authors:  Yu-Lung Tseng; Chi-Ren Huang; Chih-Hsiang Lin; Yan-Ting Lu; Cheng-Hsien Lu; Nai-Ching Chen; Chiung-Chih Chang; Wen-Neng Chang; Yao-Chung Chuang
Journal:  Medicine (Baltimore)       Date:  2014-09       Impact factor: 1.889
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.